BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance |
| April 02, 2019 | April 2019 Bond Updates |
|
BERGEN, Norway, April 2, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces preclinical data strengthening bemcentinib's broad potential in reversing... |
| View more at: https://www.prnewswire.com:443/news-releases/bergenbio-preclinical-data-presented-at-aacr-reinforces-bemcentinibs-potential-to-reverse-tumour-immunosuppression-and-therapy-resistance-300822529.html |
| Related News |